Open Access Open Access  Restricted Access Subscription Access

Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis


Affiliations
1 Department of Hepatobiliary Surgery,The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China
 

Background: The long-term prognosis after curative therapy for hepatitis B virus- (HBV-) related hepatocellular carcinoma (HCC) remains unsatisfactory due to the high incidence of recurrence. The effect of treatment with nucleotide analogues (NAs) in patients with HBV-related HCC after curative therapy remains unclear. Objective:To assess the impact of usingNAs after curative therapy. Method. A computerized literature search was performed; eligible studies were identified from databases. The pooled risk ratios (RRs) and 95% CIs were calculated using Review Manager 5.3. Result: The meta-analysis included a total of 15 studies with 8060 patients. The one-year and three-year recurrence (one-year recurrence: RR 0.41 [95% CI 0.28 to 0.61]; P < 0.00001; three-year recurrence: RR 0.63 [95% CI 0.43 to 0.94]; P = 0.001) and the one-, three-, and five-year overall survival (OS) and disease free survival (DFS) were significantly better in the treatment group. Conclusion: NAs can reduce the recurrence and improve the prognosis of HBV-related HCC after curative therapy.
User
Notifications
Font Size

Abstract Views: 95

PDF Views: 0




  • Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis

Abstract Views: 95  |  PDF Views: 0

Authors

Peng Yuan
Department of Hepatobiliary Surgery,The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China
Peng Chen
Department of Hepatobiliary Surgery,The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China
Yeben Qian
Department of Hepatobiliary Surgery,The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China

Abstract


Background: The long-term prognosis after curative therapy for hepatitis B virus- (HBV-) related hepatocellular carcinoma (HCC) remains unsatisfactory due to the high incidence of recurrence. The effect of treatment with nucleotide analogues (NAs) in patients with HBV-related HCC after curative therapy remains unclear. Objective:To assess the impact of usingNAs after curative therapy. Method. A computerized literature search was performed; eligible studies were identified from databases. The pooled risk ratios (RRs) and 95% CIs were calculated using Review Manager 5.3. Result: The meta-analysis included a total of 15 studies with 8060 patients. The one-year and three-year recurrence (one-year recurrence: RR 0.41 [95% CI 0.28 to 0.61]; P < 0.00001; three-year recurrence: RR 0.63 [95% CI 0.43 to 0.94]; P = 0.001) and the one-, three-, and five-year overall survival (OS) and disease free survival (DFS) were significantly better in the treatment group. Conclusion: NAs can reduce the recurrence and improve the prognosis of HBV-related HCC after curative therapy.